A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
Clinical trial NCT03535194 · COMPLETED
Trial details
- NCT number
- NCT03535194
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-26
- Primary completion
- 2020-03-05
- Enrollment
- 1484
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.